News

Resident News

Caelus Health and Nestlé Health Science sign exclusive global development & option agreement on Caelus’ microbiome-based food supplements

By JLABS

Read full story
Resident News

Syndesi Therapeutics announces successful completion of first-in-human Phase I study of novel SV2A modulator

By JLABS

Read full story
Other news

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.

By JLABS

Read full story
Other news

Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment

By JLABS

Read full story
Other news

Calypso Biotech BV secures 20 Million EUR in Series A Financing to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases

By JLABS

Read full story
Other news

Genome Biologics wins prestigious Horizon 2020 EU Phase 2 grant award

By JLABS

Read full story
In the media

Johnson & Johnson Opens JLABS @ NYC

By Global Cosmetic Industry

Read full story
Other news

Riding the Start-Up Roller Coaster: What It's Really Like to Be a Healthcare Entrepreneur

By Leena Rao

Read full story
Other news

IDEAYA Biosciences raised a $94M crossover Series B financing to develop next generation biomarker-enabled synthetic lethality therapies.

By Ideaya Biosciences

Read full story
Other news

Sirenas LLC. annouced today they have entered a muti-target research collaboration agreement with Bristol-Myers Squibb to deploy a drug discovery platform against undisclosed challenging therapeutic targets

By JLABS

Read full story
Other news

Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials

By JLABS

Read full story
Other news

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

By JLABS

Read full story
Other news

Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies

By JLABS

Read full story
Other news

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, announced they are entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates

By JLABS

Read full story
Other news

JLABS TMC Company finds Growth in Shrinking Cells

By JLABS

Read full story